Ghana Pharmaceuticals and Healthcare Report Q4 2017
Ghana's pharmaceutical and healthcare markets will continue to be seen as one of the moreattractive prospects in West Africa, however it's potential to attract large-scale investment is marred by theelevated industry-specific risks. In particular, the country's stable economic and political regime bode wellfor investment over the coming years, yet the small pharmaceutical market size will ensure this is focussedwithin the generic drug sector. Weak regulatory procedures and operational risks will act as deterrents tomultinational company investment the over the coming years.
Headline Expenditure Projections
Pharmaceuticals: GHS1.2bn (USD302mn) in 2016 to GHS1.3bn (USD928mn) in 2017; +8.6% in localcurrency terms and -1.1% in US dollar terms. Forecast in line with Q317.
Healthcare: GHS4.8bn (USD1.21bn) in 2016 to GHS5.2bn (USD1.20bn) in 2017; +8.9% in localcurrency terms and -0.9% in US dollar terms. Forecast in line with Q317.